Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
about
Natural Phytochemicals in the Treatment and Prevention of Dementia: An OverviewTreatment of psychosis and dementia in Parkinson's disease.Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a case report.Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literatureLong-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.Dementia with lewy bodies: diagnosis and management for primary care providers.Treatment of Visual Hallucinations in Schizophrenia by Acetylcholinesterase Inhibitors: a case reportDonepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial.Combination therapies: The next logical Step for the treatment of synucleinopathies?Distinguishing Lewy body dementias from Alzheimer's disease.Clinical features of dementia with lewy bodies in 35 Chinese patients.Hallucinations in neurodegenerative diseases.The role of phytochemicals in the treatment and prevention of dementia.Dementia With Lew Body: Impacts of Surgery.Therapeutic approaches in Parkinson's disease and related disorders.Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study.Improvement in delusions and hallucinations in patients with dementia with Lewy bodies upon administration of yokukansan, a traditional Japanese medicine.
P2860
Q26750581-76CA1038-E6F2-416D-817C-78A7A08E611AQ30358337-BDAAE435-DF4F-4C9A-B811-0BFCD943AC9DQ33686420-6696CD8F-DC11-471A-9799-A74EFABB9656Q33686426-5DFEBB4F-F7AA-47F8-81F1-5F065EF947C1Q35114375-82FE0A72-6332-48E7-B6EC-A241C08846ECQ35703007-F549E04C-8862-4C8C-91A2-CE81EA32DD7EQ36092585-54C7C1D3-1646-450D-80F1-4D7390351497Q36419270-E306B1BD-DF72-4FBA-946B-DDD9B8150DBDQ36563062-9ED8CD12-4B9D-480B-9ECE-D17D3E41B22AQ36998833-4287DDE8-0C55-45DA-AB14-633275A60C67Q37497482-C8186FF4-238F-4078-87E0-70C25E184C24Q37876971-2B9C58FA-B50D-4D32-9860-413240DB56A6Q37884566-53D7E2F8-D64D-4B59-A063-84CCD8B07EF5Q38501488-AEC46A30-6972-4AA0-A4CF-FD3DF8106F64Q38691406-290FE88B-5E22-43E6-B304-D7BDE5F0A07AQ42614000-60C8D7B6-07C0-464C-89E7-9BF376C0D310Q48203066-374491F7-5064-43E7-A2BC-8252B68BEDD5
P2860
Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Efficacy and safety of galanta ...... s: a 24-week open-label study.
@en
Efficacy and safety of galanta ...... s: a 24-week open-label study.
@nl
type
label
Efficacy and safety of galanta ...... s: a 24-week open-label study.
@en
Efficacy and safety of galanta ...... s: a 24-week open-label study.
@nl
prefLabel
Efficacy and safety of galanta ...... s: a 24-week open-label study.
@en
Efficacy and safety of galanta ...... s: a 24-week open-label study.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of galanta ...... es: a 24-week open-label study
@en
P2093
David Lichter
Donald Royall
Keith Edwards
Linda Hershey
Martin Farlow
Stewart Johnson
P2860
P304
P356
10.1159/000101512
P577
2007-04-03T00:00:00Z